Skip to main content

Table 1 Cataract surgery in uveitic eyes and the use of intraocular lenses: comparison of major studies in literature

From: Controversies in intraocular lens implantation in pediatric uveitis

Sources

No. of patients

Etiology

Age at presentation of Ds in years (median)

Age at Cataract surgery (years)

PCIOL (in the bag) (n =eyes)

Aphakia (n=eyes)

Complications (n=eyes)

Immunosuppression

Follow-up

Comments

Visual outcome pseudophakia (n=eyes)

Visual outcome aphakia (n=eyes)

Probst and Holland [17] (1996)

7 (8 eyes)

JIA

 

Adults (5)

<10 (2)

PMMA

 

Glaucoma (4), PCO (5)

Steroids

16.6 months

 

All >20/40

 

Lundvall and Zetterstrom [28] (2000)

7 (10 eyes)

JIA

 

3.5–10

6.5 (mean)

HSM-PMMA 10

 

Glaucoma (7), PCO (5), 2nd Sx for membranes (8)

Steroids, methotrexate

28 months

Uveitis controlled

20/20–20/50(8) <20/50(2)

 

BenEzra and Cohen [15] (2000)

17 (20 eyes)

JIA (8)

 

4–17

10 PMMA (7), diffractive (3)

7

Glaucoma (4), PS (3), CME (3)

Steroids

60 months

In U/L, CL poorly tolerated, JIA results guarded, uveitis active

JRA

6/9–6/6(1)

6/60(1)

6/240(3)

JRA

6/9–6/6(1)

6/240(3)

Lam et al.[21] (2003)

5 (6 eyes)

JIA (5)

8.5

7–12

8.5 (median)

6 PMMA (4), HSM-PMMA (1), acrylic hydrophobic (1)

 

PCO (6), glaucoma (2), CME (1)

Methotrexate

43.5 months

Uveitis controlled

ALL >20/40

 

Nemet et al. [16] (2007)

18 (19 eyes)

JIA (10), non-JIA (9)

JIA (0.9–14) Non-JIA (4.6–17)

JIA (11.8+/−4.6), non-JIA (17.1+/−4.5)

PMMA (7), acrylic hydrophobic (11), acrylic hydrophilic (1)

 

PCO (10), glaucoma (4), CME (1), 2nd Sx (11)

Steroids, methotrexate,

cyclosporine

45 months

No difference in visual outcome in both groups

>20/40 (13)

<20/40 (6)

 

Quinones et al. [8] (2009)

34 (48 eyes)

JIA (27), non-JIA (13)

6.7 (4–16)

9.8 (4–17)

13 PMMA

28

Glaucoma (3), PCO (4), RD (3), CME (4), membranes (2)

Steroids, methotrexate

0.3–15.7 years

(4.1 years)

Uveitis controlled,

postsegment involved (17)

92 % improved

>20/40 (8)

20/50–20/70(4)

20/80–20/200(0)

<20/400(1)

>20/40 (9)

20/50–20/70(6)

20/80–20/200(5)

<20/400(8)

Sijssens [41] (2010)

29 (48 eyes)

JIA

4.4

6.3 aphakia, 7.6 pseudophakia

29 acrylic 24, PMMA 5

19

Ocular HTN, glaucoma, CME,

optic disc involvement

Methotrexate

7 years

Uveitis controlled,

aphakic surgeries till 2002, complications same in both groups

>20/40 (25)

20/40–20/200(3)

<20/200(1)

>20/40 (13)

20/40–20/200(4)

<20/200(2)

Terrada et al. [6] (2011)

16 (22 eyes)

JIA (9), non-JIA (7)

5 years

9.5 (median)

22 HSM-PMMA

 

PCO (2), glaucoma (4), CME (3)

Methotrexate, azathioprine

6.2 years

Uveitis controlled

0.3 or better, log MAR

 
  1. HTN hypertension, CME cystoid macular edema, RD retinal detachment, PS posterior synechiae, Sx surgery